Identification of genetic subtypes in follicular lymphoma-Reference-Cited by-同舟云学术

Identification of genetic subtypes in follicular lymphoma

Published:2024-08-07 Issue:1 Volume:14 Page:
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer J.

Author:

Shelton Victoria,Detroja Rajesh,Liu Ting^ORCID,Isaev Keren,Silva Anjali,Passerini Verena,Bakhtiari Mehran,Calvente Lourdes,Hong Michael,He Michael Y.^ORCID,Modi Saloni,Hershenfeld Samantha A.,Ludvigsen Maja^ORCID,Madsen Charlotte,Hamilton-Dutoit Stephen,d’Amore Francesco Annibale,Brodtkorb Marianne,Johnson Nathalie A.,Baetz Tara,LeBrun David,Tobin Josh W. D.,Gandhi Maher K.^ORCID,Mungall Andrew J.,Xu Wei,Ben-Neriah Susana,Steidl Christian^ORCID,Delabie Jan^ORCID,Tremblay-LeMay Rosemarie,Jegede Opeyemi,Weigert Oliver^ORCID,Kahl Brad^ORCID,Evens Andrew M.,Kridel Robert^ORCID

Funder

Terry Fox Research Institute

Leukemia and Lymphoma Society

Leukemia and Lymphoma Society of Canada

Princess Margaret Cancer Foundation

Gouvernement du Canada | Canadian Institutes of Health Research

Else Kröner-Fresenius-Stiftung

Deutsche Forschungsgemeinschaft

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41408-024-01111-w.pdf

Reference45 articles.

1. Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin’s lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin’s Lymphoma Classification Project. Ann Oncol. 1998;9:717–20.

2. Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. 2015;33:2516–22.

3. Mozessohn L, Cheung MC, Crump M, Buckstein R, Berinstein N, Imrie K, et al. Chemoimmunotherapy resistant follicular lymphoma: predictors of resistance, association with transformation and prognosis. Leuk Lymphoma. 2014;55:2502–7.

4. Freeman CL, Kridel R, Moccia AA, Savage KJ, Villa DR, Scott DW, et al. Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma. Blood. 2019;134:761–4.

5. Casulo C, Dixon JG, Le-Rademacher J, Hoster E, Hochster HS, Hiddemann W, et al. Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. Blood. 2022;139:1684–93.